Warm autoimmune hemolytic anemia and IgM-monoclonal gammopathy following BNT162b2 COVID-19 vaccine in a patient with splenic marginal zone lymphoma

DOI Web Site PubMed 1 Citations
  • SOGABE Nobuhiro
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • KUNO Masatomo
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • NAKAGAMA Yu
    Department of Parasitology & Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University
  • MAKUUCHI Yosuke
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • HARADA Naonori
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • TAKAKUWA Teruhito
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • OKAMURA Hiroshi
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • HIROSE Asao
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • NISHIMOTO Mitsutaka
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • NAKASHIMA Yasuhiro
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • KOH Hideo
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • NAKAMAE Mika
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • KIDO Yasutoshi
    Department of Parasitology & Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University
  • NAKAMAE Hirohisa
    Department of Hematology, Graduate School of Medicine, Osaka City University
  • HINO Masayuki
    Department of Hematology, Graduate School of Medicine, Osaka City University

Bibliographic Information

Other Title
  • BNT162b2 COVID-19ワクチン接種後に温式自己免疫性溶血性貧血とIgM-M蛋白血症を発症した脾辺縁帯リンパ腫
  • BNT162b2 COVID-19 ワクチン セッシュ ゴ ニ オンシキ ジコ メンエキセイ ヨウケツセイ ヒンケツ ト IgM-M タンパク ケッショウ オ ハッショウ シタ ヒヘンエンタイ リンパシュ

Search this article

Description

<p>There is currently no evidence that a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine might be associated with the development of autoimmune hemolytic anemia or disease progression in patients with mature B-cell neoplasm. Our patient was a 71-year-old man with indolent mature B-cell neoplasm who had been monitored for many years without treatment. After receiving the second dose of the BNT162b2 mRNA COVID-19 vaccine, he developed severe warm autoimmune hemolytic anemia. Although steroid therapy improved his anemia, he continued to develop IgM-monoclonal gammopathy, renal insufficiency, and splenomegaly. He was diagnosed with splenic marginal zone lymphoma after undergoing splenectomy. The splenectomy improved the patient’s symptoms. We assessed his SARS-CoV-2 specific antibody response, but the patient’s serologic response to the vaccine was impaired. In patients with mature B-cell neoplasm, a non-specific immune response after vaccination might be associated with paraneoplastic syndromes.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 63 (10), 1379-1385, 2022

    The Japanese Society of Hematology

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top